X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK vs NOVARTIS - Comparison Results

MERCK    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK NOVARTIS MERCK/
NOVARTIS
 
P/E (TTM) x 52.5 429.0 12.2% View Chart
P/BV x 9.2 30.3 30.3% View Chart
Dividend Yield % 0.4 1.5 24.5%  

Financials

 MERCK   NOVARTIS
EQUITY SHARE DATA
    MERCK
Dec-17
NOVARTIS
Mar-18
MERCK/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,358758 179.1%   
Low Rs933579 161.1%   
Sales per share (Unadj.) Rs665.0228.4 291.2%  
Earnings per share (Unadj.) Rs56.631.7 178.3%  
Cash flow per share (Unadj.) Rs72.532.8 221.2%  
Dividends per share (Unadj.) Rs15.0010.00 150.0%  
Dividend yield (eoy) %1.31.5 87.6%  
Book value per share (Unadj.) Rs441.7297.1 148.7%  
Shares outstanding (eoy) m16.6024.69 67.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.9 58.8%   
Avg P/E ratio x20.221.1 96.1%  
P/CF ratio (eoy) x15.820.4 77.4%  
Price / Book Value ratio x2.62.2 115.2%  
Dividend payout %26.531.5 84.2%   
Avg Mkt Cap Rs m19,01116,505 115.2%   
No. of employees `0001.50.7 231.1%   
Total wages/salary Rs m1,6961,445 117.4%   
Avg. sales/employee Rs Th7,150.08,441.3 84.7%   
Avg. wages/employee Rs Th1,098.72,163.6 50.8%   
Avg. net profit/employee Rs Th608.21,173.1 51.8%   
INCOME DATA
Net Sales Rs m11,0405,639 195.8%  
Other income Rs m2401,718 13.9%   
Total revenues Rs m11,2797,357 153.3%   
Gross profit Rs m1,376-63 -2,201.9%  
Depreciation Rs m26425 1,043.5%   
Interest Rs m055 0.0%   
Profit before tax Rs m1,3521,575 85.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m583792 73.6%   
Profit after tax Rs m939784 119.8%  
Gross profit margin %12.5-1.1 -1,124.7%  
Effective tax rate %43.150.3 85.8%   
Net profit margin %8.513.9 61.2%  
BALANCE SHEET DATA
Current assets Rs m7,5239,522 79.0%   
Current liabilities Rs m2,2533,296 68.3%   
Net working cap to sales %47.7110.4 43.2%  
Current ratio x3.32.9 115.6%  
Inventory Days Days5237 142.5%  
Debtors Days Days4128 142.7%  
Net fixed assets Rs m1,24046 2,695.0%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m7,1677,213 99.4%   
Net worth Rs m7,3337,336 99.9%   
Long term debt Rs m00-   
Total assets Rs m9,91211,105 89.3%  
Interest coverage xNM29.5-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.5 219.3%   
Return on assets %9.57.6 125.4%  
Return on equity %12.810.7 119.9%  
Return on capital %20.822.2 93.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,01561 1,674.3%   
Fx outflow Rs m3,0433,630 83.8%   
Net fx Rs m-2,028-3,570 56.8%   
CASH FLOW
From Operations Rs m5371,610 33.3%  
From Investments Rs m-476687 -69.3%  
From Financial Activity Rs m-220-2,677 8.2%  
Net Cashflow Rs m-160-380 42.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 2.0 910.0%  
FIIs % 1.0 1.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 21.5 135.3%  
Shareholders   28,591 41,647 68.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK With:   BIOCON   WOCKHARDT  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare MERCK With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Higher, IPO Buzz, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MERCK SHARE PRICE


Jun 26, 2019 09:21 AM

TRACK MERCK

COMPARE MERCK WITH

MARKET STATS